2023 Q1 Form 10-K Financial Statement
#000149315223010223 Filed on March 31, 2023
Income Statement
Concept | 2023 Q1 | 2022 Q4 | 2022 |
---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $1.302M | $1.184M | $5.769M |
YoY Change | -11.43% | -29.57% | 6.71% |
% of Gross Profit | |||
Research & Development | $1.617M | $1.884M | $7.736M |
YoY Change | -5.22% | -16.49% | 31.68% |
% of Gross Profit | |||
Depreciation & Amortization | $25.00K | $33.00K | $102.0K |
YoY Change | 19.05% | 17.86% | 34.21% |
% of Gross Profit | |||
Operating Expenses | $1.617M | $3.068M | $7.736M |
YoY Change | -49.09% | -22.07% | -31.88% |
Operating Profit | -$2.919M | -$13.28M | |
YoY Change | -8.09% | 16.94% | |
Interest Expense | $66.00K | $75.00K | $118.0K |
YoY Change | -607.69% | -3.85% | 168.18% |
% of Operating Profit | |||
Other Income/Expense, Net | -$5.000K | ||
YoY Change | |||
Pretax Income | -$2.853M | -$2.998M | -$13.17M |
YoY Change | -10.54% | -22.31% | 16.4% |
Income Tax | |||
% Of Pretax Income | |||
Net Earnings | -$2.853M | -$2.998M | -$13.17M |
YoY Change | -10.54% | -22.31% | 16.4% |
Net Earnings / Revenue | |||
Basic Earnings Per Share | -$0.36 | -$1.81 | |
Diluted Earnings Per Share | -$0.36 | -$0.39 | -$1.81 |
COMMON SHARES | |||
Basic Shares Outstanding | 8.131M shares | 7.891M shares | 7.260M shares |
Diluted Shares Outstanding | 8.013M shares | 7.260M shares |
Balance Sheet
Concept | 2023 Q1 | 2022 Q4 | 2022 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $5.057M | $8.205M | $8.205M |
YoY Change | -59.45% | -47.04% | -47.04% |
Cash & Equivalents | $2.150M | $2.442M | $2.442M |
Short-Term Investments | $2.907M | $5.763M | $5.763M |
Other Short-Term Assets | $524.0K | $506.0K | $506.0K |
YoY Change | 85.82% | 137.56% | 137.56% |
Inventory | |||
Prepaid Expenses | $429.0K | ||
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $5.581M | $8.814M | $8.814M |
YoY Change | -56.23% | -44.49% | -44.49% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $196.0K | $221.0K | $723.0K |
YoY Change | -78.92% | -9.43% | -18.58% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | |||
YoY Change | |||
Total Long-Term Assets | $627.0K | $723.0K | $723.0K |
YoY Change | -32.58% | -18.58% | -18.58% |
TOTAL ASSETS | |||
Total Short-Term Assets | $5.581M | $8.814M | $8.814M |
Total Long-Term Assets | $627.0K | $723.0K | $723.0K |
Total Assets | $6.208M | $9.537M | $9.537M |
YoY Change | -54.63% | -43.12% | -43.12% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $224.0K | $116.0K | $116.0K |
YoY Change | 5.66% | -58.42% | -58.42% |
Accrued Expenses | $743.0K | $1.670M | $1.953M |
YoY Change | -49.21% | 17.03% | 14.55% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $1.233M | $2.069M | $2.069M |
YoY Change | -26.39% | 4.28% | 4.28% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $127.0K | $179.0K | $179.0K |
YoY Change | -67.1% | -55.47% | -55.47% |
Total Long-Term Liabilities | $127.0K | $179.0K | $179.0K |
YoY Change | -67.1% | -55.47% | -55.47% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $1.233M | $2.069M | $2.069M |
Total Long-Term Liabilities | $127.0K | $179.0K | $179.0K |
Total Liabilities | $1.360M | $2.248M | $2.248M |
YoY Change | -34.01% | -5.78% | -5.78% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$71.61M | -$68.76M | |
YoY Change | 23.69% | ||
Common Stock | $76.46M | $76.05M | |
YoY Change | 8.68% | ||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $4.848M | $7.289M | $7.289M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $6.208M | $9.537M | $9.537M |
YoY Change | -54.63% | -43.12% | -43.12% |
Cashflow Statement
Concept | 2023 Q1 | 2022 Q4 | 2022 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$2.853M | -$2.998M | -$13.17M |
YoY Change | -10.54% | -22.31% | 16.4% |
Depreciation, Depletion And Amortization | $25.00K | $33.00K | $102.0K |
YoY Change | 19.05% | 17.86% | 34.21% |
Cash From Operating Activities | -$3.203M | -$2.463M | -$11.55M |
YoY Change | 6.52% | -14.69% | 23.47% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $1.000K | $84.00K | |
YoY Change | -102.27% | -221.74% | |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $2.883M | -$3.752M | -$3.752M |
YoY Change | -225.11% | -214.78% | |
Cash From Investing Activities | $2.883M | -$3.753M | -$3.836M |
YoY Change | -18118.75% | -227.01% | -219.88% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 4.324M | $4.324M | |
YoY Change | |||
NET CHANGE | |||
Cash From Operating Activities | -$3.203M | -2.463M | -$11.55M |
Cash From Investing Activities | $2.883M | -3.753M | -$3.836M |
Cash From Financing Activities | 4.324M | $4.324M | |
Net Change In Cash | -$320.0K | -1.892M | -$11.06M |
YoY Change | -89.41% | -2882.35% | |
FREE CASH FLOW | |||
Cash From Operating Activities | -$3.203M | -$2.463M | -$11.55M |
Capital Expenditures | $1.000K | $84.00K | |
Free Cash Flow | -$3.203M | -$2.464M | -$11.63M |
YoY Change | 7.09% | -13.33% | 25.29% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2022 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0000883975 | |
CY2022 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2022 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2021Q4 | us-gaap |
Deposits Assets Current
DepositsAssetsCurrent
|
usd | |
CY2022Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2021 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
usd | |
CY2021 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
usd | |
CY2021 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
usd | |
CY2021 | us-gaap |
Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
|
usd | |
CY2022 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
usd | |
CY2021 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
usd | |
CY2022 | MBOT |
Proceed From Sale And Maturity Of Marketable Securities
ProceedFromSaleAndMaturityOfMarketableSecurities
|
usd | |
CY2021 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
usd | |
CY2021 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
usd | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
pure | |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
pure | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
usd | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
usd | |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
usd | |
CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
usd | |
CY2022 | dei |
Document Type
DocumentType
|
10-K | |
CY2022 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
CY2022 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2022-12-31 | |
CY2022 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2022 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2022 | |
CY2022 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2022 | dei |
Entity File Number
EntityFileNumber
|
000-19871 | |
CY2022 | dei |
Entity Registrant Name
EntityRegistrantName
|
MICROBOT MEDICAL INC. | |
CY2022 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2022 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
94-3078125 | |
CY2022 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
25 Recreation Park Drive | |
CY2022 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Unit 108 | |
CY2022 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Hingham | |
CY2022 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MA | |
CY2022 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
02043 | |
CY2022 | dei |
City Area Code
CityAreaCode
|
(781) | |
CY2022 | dei |
Local Phone Number
LocalPhoneNumber
|
875-3605 | |
CY2022 | dei |
Security12b Title
Security12bTitle
|
Common Stock, Par value $0.01 | |
CY2022 | dei |
Trading Symbol
TradingSymbol
|
MBOT | |
CY2022 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
CY2022 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2022 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2022 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2022 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2022 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2022 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2022 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2022 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
false | |
CY2022 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2022Q2 | dei |
Entity Public Float
EntityPublicFloat
|
34521094 | usd |
CY2023Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
8130628 | shares |
CY2022 | dei |
Auditor Firm
AuditorFirmId
|
1197 | |
CY2022 | dei |
Auditor Name
AuditorName
|
Brightman Almagor Zohar & Co | |
CY2022 | dei |
Auditor Location
AuditorLocation
|
Tel Aviv, Israel | |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2442000 | usd |
CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
13493000 | usd |
CY2022Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
5760000 | usd |
CY2021Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
1999000 | usd |
CY2022Q4 | us-gaap |
Deposits Assets Current
DepositsAssetsCurrent
|
3000 | usd |
CY2022Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
77000 | usd |
CY2021Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
87000 | usd |
CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
532000 | usd |
CY2021Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
300000 | usd |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
8814000 | usd |
CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
15879000 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
221000 | usd |
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
244000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
502000 | usd |
CY2021Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
644000 | usd |
CY2022Q4 | us-gaap |
Assets
Assets
|
9537000 | usd |
CY2021Q4 | us-gaap |
Assets
Assets
|
16767000 | usd |
CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
116000 | usd |
CY2021Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
279000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
283000 | usd |
CY2021Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
278000 | usd |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1670000 | usd |
CY2021Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1427000 | usd |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2069000 | usd |
CY2021Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1984000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
179000 | usd |
CY2021Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
402000 | usd |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
2248000 | usd |
CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
2386000 | usd |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
CY2021Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
60000000 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
60000000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
7890628 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
7890628 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
7108133 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
7108133 | shares |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
80000 | usd |
CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
72000 | usd |
CY2022Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
75970000 | usd |
CY2021Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
69902000 | usd |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-68761000 | usd |
CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-55593000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
7289000 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14381000 | usd |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
9537000 | usd |
CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
16767000 | usd |
CY2022 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
7736000 | usd |
CY2021 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6153000 | usd |
CY2022 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5545000 | usd |
CY2021 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5204000 | usd |
CY2022 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13281000 | usd |
CY2021 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-11357000 | usd |
CY2022 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
118000 | usd |
CY2021 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
44000 | usd |
CY2022 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-5000 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13168000 | usd |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11313000 | usd |
CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.81 | |
CY2021 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.59 | |
CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
7260344 | shares |
CY2021 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
7108133 | shares |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14381000 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14381000 | usd |
CY2022 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
4324000 | usd |
CY2022 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1752000 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13168000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
7289000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
7289000 | usd |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
24308000 | usd |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
24308000 | usd |
CY2021 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1386000 | usd |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11313000 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14381000 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14381000 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13168000 | usd |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11313000 | usd |
CY2022 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
102000 | usd |
CY2021 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
76000 | usd |
CY2022 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
12000 | usd |
CY2022 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-5000 | usd |
CY2022 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1752000 | usd |
CY2021 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1386000 | usd |
CY2022 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-13000 | usd |
CY2021 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-177000 | usd |
CY2022 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
-241000 | usd |
CY2021 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
320000 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-11549000 | usd |
CY2021 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-9354000 | usd |
CY2022 | us-gaap |
Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
|
3000 | usd |
CY2022 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
84000 | usd |
CY2021 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
69000 | usd |
CY2021 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
270000 | usd |
CY2022 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
3749000 | usd |
CY2021 | MBOT |
Proceed From Sale And Maturity Of Marketable Securities
ProceedFromSaleAndMaturityOfMarketableSecurities
|
2999000 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-3836000 | usd |
CY2021 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
3200000 | usd |
CY2022 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
4324000 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
4324000 | usd |
CY2022 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-11061000 | usd |
CY2021 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-6154000 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
13580000 | usd |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
19734000 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
2519000 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
13580000 | usd |
CY2022 | us-gaap |
Interest Paid Net
InterestPaidNet
|
51000 | usd |
CY2021 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1000 | usd |
CY2022 | us-gaap |
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
|
103000 | usd |
CY2021 | us-gaap |
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
|
69000 | usd |
CY2022 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p id="xdx_802_eus-gaap--NatureOfOperations_zNb5rAtlQ3Yb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_82F_zReBNzFYssJj">GENERAL</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 85.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description of business:</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot Medical Inc. (the “Company”) is a pre-clinical medical device company specializing in the research, design and development of next generation micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incorporated on <span id="xdx_90C_edei--EntityIncorporationDateOfIncorporation_c20220101__20221231_zxPU93kZOCw9" title="Date of incorporation">August 2, 1988</span> in the State of Delaware under the name Cellular Transplants, Inc. The original Certificate of Incorporation was restated on February 14, 1992 to change the name of the Company to Cyto Therapeutics, Inc. On May 24, 2000, the Certificate of Incorporation as restated was further amended to change the name of the Company to StemCells, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (“Microbot Israel”). On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “MBOT”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its subsidiary are sometimes collectively referred to as the “Company” as the context may require.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk Factors:</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To date, the Company has not generated revenues from its operations. As of December 31, 2022, the Company had cash equivalents and marketable securities balance of approximately $<span id="xdx_903_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn3n3_c20221231_z9lZQeK5WOB8" title="Cash equivalents and marketable securities">8,202</span> excluding encumbered cash, which management believes is sufficient to fund its operations for additional 4 months form the date of this annual report. As of the issuance date, there is a substantial doubt as to the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">MICROBOT MEDICAL INC.</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>U.S. dollars in thousands</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>(Except share and per share data)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to continuing research and development activities, the Company expects to continue to incur additional losses for the foreseeable future. While management of the Company believes that it has sufficient funds until August 2023, the Company will seek to raise additional funds through future issuances of either debt and/or equity securities and possibly additional grants from the Israeli Innovation Authority and other government institutions. The Company’s ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company’s stock, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C. </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates:</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.65pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | |
CY2022 | dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
1988-08-02 | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
8202000 | usd |
CY2022Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
77000 | usd |
CY2021Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
87000 | usd |
CY2022 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zXlDjgrGfgma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zLXsSRVZPcBj">Concentrations of credit risk</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments which potentially subject the Company to credit risk consist primarily of cash and cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.</span></p> | |
CY2022Q4 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
2442000 | usd |
CY2021Q4 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
13493000 | usd |
CY2022Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
5760000 | usd |
CY2021Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
1999000 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
8202000 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
15492000 | usd |
CY2022 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
12000 | usd |
CY2022Q4 | us-gaap |
Government Contract Receivable
GovernmentContractReceivable
|
103000 | usd |
CY2021Q4 | us-gaap |
Government Contract Receivable
GovernmentContractReceivable
|
174000 | usd |
CY2022Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
429000 | usd |
CY2021Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
126000 | usd |
CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
532000 | usd |
CY2021Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
300000 | usd |
CY2019Q4 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P5Y | |
CY2022 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
16000 | usd |
CY2022 | MBOT |
Bank Guarantee Issued
BankGuaranteeIssued
|
54000 | usd |
CY2022 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
344000 | usd |
CY2021 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
330000 | usd |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
312000 | usd |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
181000 | usd |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
2000 | usd |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
495000 | usd |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
33000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
462000 | usd |
CY2022Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
298000 | usd |
CY2021Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
396000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y | |
CY2021Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y | |
CY2022Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.09 | pure |
CY2021Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.09 | pure |
CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
608000 | usd |
CY2021Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
533000 | usd |
CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
387000 | usd |
CY2021Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
289000 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
221000 | usd |
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
244000 | usd |
CY2022Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1372000 | usd |
CY2021Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1031000 | usd |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1670000 | usd |
CY2021Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1427000 | usd |
CY2020Q1 | us-gaap |
Loss Contingency Loss In Period
LossContingencyLossInPeriod
|
151000 | usd |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
7890628 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
7890628 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
7108133 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
7108133 | shares |
CY2022Q4 | us-gaap |
Warrant Exercise Price Increase
WarrantExercisePriceIncrease
|
0.0001 | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
185000 | usd |
CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
974000 | usd |
CY2022Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
185000 | usd |
CY2021Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
815000 | usd |
CY2022Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
2036000 | usd |
CY2022 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y14D | |
CY2022Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
1507137 | shares |
CY2021Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
997148 | shares |
CY2022 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
|
P7Y7M6D | |
CY2021 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
|
P7Y7M6D | |
CY2022Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
|
899609 | shares |
CY2021Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
|
568053 | shares |
CY2022 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
|
0.01 | |
CY2022 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1752000 | usd |
CY2021 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1386000 | usd |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
1.112 | pure |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
1.617 | pure |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
1.183 | pure |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
1.343 | pure |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.017 | pure |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.037 | pure |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.004 | pure |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.012 | pure |
CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y2M12D | |
CY2022 | MBOT |
Employee Stock Ownership Plan Expenses To Directors Related Party
EmployeeStockOwnershipPlanExpensesToDirectorsRelatedParty
|
301000 | usd |
CY2021 | MBOT |
Employee Stock Ownership Plan Expenses To Directors Related Party
EmployeeStockOwnershipPlanExpensesToDirectorsRelatedParty
|
91000 | usd |
CY2022 | MBOT |
Insurance For Directors And Executives
InsuranceForDirectorsAndExecutives
|
722000 | usd |
CY2021 | MBOT |
Insurance For Directors And Executives
InsuranceForDirectorsAndExecutives
|
727000 | usd |
CY2022 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
4562000 | usd |
CY2021 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
3876000 | usd |
CY2022 | MBOT |
Bonus To Ceo And Executive Offices Related Party
BonusToCeoAndExecutiveOfficesRelatedParty
|
581000 | usd |
CY2021 | MBOT |
Bonus To Ceo And Executive Offices Related Party
BonusToCeoAndExecutiveOfficesRelatedParty
|
310000 | usd |
CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y3M18D | |
CY2022 | us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
2067000 | usd |
CY2021 | us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
1912000 | usd |
CY2022 | MBOT |
Employee Stock Ownership Plan Expenses To Chief Executive Officer And Executive Officers
EmployeeStockOwnershipPlanExpensesToChiefExecutiveOfficerAndExecutiveOfficers
|
1172000 | usd |
CY2021 | MBOT |
Employee Stock Ownership Plan Expenses To Chief Executive Officer And Executive Officers
EmployeeStockOwnershipPlanExpensesToChiefExecutiveOfficerAndExecutiveOfficers
|
846000 | usd |
CY2022 | us-gaap |
Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
|
300000 | usd |
CY2021 | us-gaap |
Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
|
300000 | usd |
CY2022 | MBOT |
Noninterest Expense Directors Fees Related Party
NoninterestExpenseDirectorsFeesRelatedParty
|
75000 | usd |
CY2021 | MBOT |
Noninterest Expense Directors Fees Related Party
NoninterestExpenseDirectorsFeesRelatedParty
|
75000 | usd |
CY2022 | MBOT |
Labor And Related Expense Related Party
LaborAndRelatedExpenseRelatedParty
|
92000 | usd |
CY2021 | MBOT |
Labor And Related Expense Related Party
LaborAndRelatedExpenseRelatedParty
|
28000 | usd |
CY2022 | us-gaap |
Costs And Expenses Related Party
CostsAndExpensesRelatedParty
|
748000 | usd |
CY2021 | us-gaap |
Costs And Expenses Related Party
CostsAndExpensesRelatedParty
|
413000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
|
113393000 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
|
109483000 | usd |
CY2022Q4 | MBOT |
Deferred Tax Assets Operation Lease Liabilities
DeferredTaxAssetsOperationLeaseLiabilities
|
105000 | usd |
CY2021Q4 | MBOT |
Deferred Tax Assets Operation Lease Liabilities
DeferredTaxAssetsOperationLeaseLiabilities
|
156000 | usd |
CY2022Q4 | MBOT |
Deferred Tax Assets Accrued Vacation Pay
DeferredTaxAssetsAccruedVacationPay
|
71000 | usd |
CY2021Q4 | MBOT |
Deferred Tax Assets Accrued Vacation Pay
DeferredTaxAssetsAccruedVacationPay
|
45000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
113569000 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
110684000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
113455000 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
110536000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
114000 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
148000 | usd |
CY2022Q4 | MBOT |
Deferred Tax Liabilities Operating Leases Rightof Use Assets
DeferredTaxLiabilitiesOperatingLeasesRightofUseAssets
|
114000 | usd |
CY2021Q4 | MBOT |
Deferred Tax Liabilities Operating Leases Rightof Use Assets
DeferredTaxLiabilitiesOperatingLeasesRightofUseAssets
|
148000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
114000 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
148000 | usd |
CY2022 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
2922000 | usd |
CY2021 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
2513000 | usd |
CY2022 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-2922000 | usd |
CY2021 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-2513000 | usd |